Sigrid Therapeutics publishes SHINE clinical trial results
The trial, published in eClinicalMedicine, shows SiPore supports metabolic health by entrapping digestive enzymes.
See the latest news and media coverage for Sigrid Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Developer of bioengineered silica for metabolic health
sigridthx.comLast updated
In short: Sigrid Therapeutics appointed Claus Kjaersgaard as CEO, secured $5 million in funding, and achieved clinical validation for its SiPore technology.
The trial, published in eClinicalMedicine, shows SiPore supports metabolic health by entrapping digestive enzymes.
The peer-reviewed results validate the SiPore technology platform for metabolic health and mark a major milestone.
The medical food product uses SiPore technology to support metabolic health.
He focuses on structured commercial scaling rooted in SiPore® technology. 2026 priorities include HCP expansion, regulatory clarity, partnerships, and evidence development.
Claus Kjaersgaard becomes new CEO at Sigrid Therapeutics after the company's co-founder Sana Alajmovic has left the position for a corresponding role at Enxymatica, which Medtech Magazine...
STOCKHOLM, Jan. 21, 2026 /PRNewswire/ -- Sigrid Therapeutics (Sigrid) is a Swedish, science-driven consumer health company with a primary focus on metabolic health. Following the...
STOCKHOLM, Nov. 3, 2025 /PRNewswire/ -- SIGRID, the Swedish innovative consumer care company behind the groundbreaking Glucose Stabiliser powered by patented SiPore® technology, today announced...
Sigrid Therapeutics wants to combat type 2 diabetes with a powder that is mixed with water. Now the company is raising 72 million to conduct a larger study...
Track Sigrid Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.